FLAM
VNDA icon

First Light Asset Management’s Vanda Pharmaceuticals VNDA Stock Holding History

First Light Asset Management’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-229,818
Closed -$3.29M – 65
2014
Q4 		$3.29M Buy
+229,818
New +$2.72M 1.87% 22

Other funds holding VNDA

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

First Light Asset Management's VNDA Position: Q1 2015 in Review

First Light Asset Management sold out of Vanda Pharmaceuticals (VNDA) in Q1 2015, closing a stake of 229,818 shares — an estimated $3.29M sold.

First Light Asset Management first reported a position in VNDA in Q4 2014 and held it in 1 quarter. The position peaked at $3.29M in Q4 2014. 110 funds tracked by Wall St. Rank hold VNDA as of Q1 2015.

  • First Light Asset Management reported no remaining Vanda Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
  • First Light Asset Management sold 229,818 Vanda Pharmaceuticals shares in Q1 2015, an estimated $3.29M.
  • First Light Asset Management first reported a position in Vanda Pharmaceuticals in Q4 2014 and held it in 1 quarter.
  • First Light Asset Management's Vanda Pharmaceuticals position peaked at $3.29M in Q4 2014.
  • 110 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2015.

Based on First Light Asset Management's 13F filing for Q1 2015, filed 15 May 2015.